By Christy Santhosh May 28 (Reuters) - The U.S. FDA's advisory panel will vote on Thursday on whether COVID-19 vaccines for ...
The US Food and Drug Administration (FDA) has approved Pfizer and BioNTech’s mRNA COVID-19 vaccine, Comirnaty, for people 16 years or older. The announcement represents not just the first approved ...
The Comirnaty 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, a descendant of JN.1. The Food and Drug Administration (FDA) has approved Comirnaty ® (LP.8.1-adapted monovalent ...
MedPage Today on MSN
FDA's Vaccine Panel to Weigh XFG Variant for New COVID Shots
But advisors will take a hard look at "Cicada" variant as well ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Add Yahoo as a preferred source to see more of our stories on Google. COVID-19 vaccine recommendations could be changing, according to the U.S. Food and Drug Administration. FDA leaders said on May 20 ...
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a change to the license of the Comirnaty Omicron XBB.1.5 30 micrograms/dose (single-dose vials) after it was found to meet ...
Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...
NEW YORK & MAINZ, GERMANY--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results